title: [Allogenic stem cell transplantations in lymphoma patients].
abstract: The disease recurs in a significant proportion of lymphoma patients after the first-line treatment. Intensive treatment supported by the patient's own cells (autologic stem cell transplantation) has long been utilized in selected cases, but restrictions of this form of therapy are well known. Allogenic transplantation with another person's stem cells provides a possibility to treat lymphoma having a poor prognosis even in cases where other methods of treatments have failed. Allogeneic stem cell transplantation is, however, associated with a significant risk of death.
authors.affiliation: KYS:n sisätautien klinikka, PL 1777, 70211 Kuopio.
authors.forename: Esa
authors.initials: E
authors.lastname: Jantunen
authors.forename: Sirkku
authors.initials: S
authors.lastname: Jyrkkiö
authors.forename: Outi
authors.initials: O
authors.lastname: Kuittinen
authors.forename: Tuula
authors.initials: T
authors.lastname: Lehtinen
authors.forename: Rita
authors.initials: R
authors.lastname: Janes
authors.forename: Erkki
authors.initials: E
authors.lastname: Elonen
authors.forename: Liisa
authors.initials: L
authors.lastname: Volin
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008223:Lymphoma / Q000401:mortality* / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D014184:Transplantation, Homologous